In the News

Mixed Results for Herceptin Cardiotoxicity Prevention

Admin • CCON • 12/10/2015

Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »

Read More...

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

Admin • CCON • 12/9/2015

SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »

Read More...

Can cancer itself damage the heart?

Admin • CCON • 12/3/2015

Research presented today at EuroEcho-Imaging 2015 raises the possibility that cancer itself may damage heart muscle irrespective of exposure to cancer drug therapies. Researchers from the UK’s first dedicated cardio-oncology... Read more »

Read More...

Harwich Port woman blindsided by chemotherapy

Admin • CCON • 11/29/2015

Breast cancer was a devastating diagnosis for Kathleen Mingle, a teacher who played tennis, ran and generally led an active and fit life. But the shock was compounded when she... Read more »

Read More...

CCC 2015: Improving Cardiac Care for Cancer Patients

Admin • CCON • 11/19/2015

CCS Position Statement Dr. Dent, co-founder of the Ottawa Cardiology-Oncology Clinic at The Ottawa Hospital, led the session presenting the Canada Cardiovascular Society’s (CCS) first position statement on cardiovascular complications... Read more »

Read More...

NIH Funding Opportunity: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)

Admin • CCON • 11/17/2015

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to... Read more »

Read More...

AHA: Candesartan May Preserve Cardiac Function in Breast Ca Patients

Admin • CCON • 11/11/2015

ORLANDO — An angiotensin II receptor blocker may help to preserve cardiac function in patients receiving treatment for breast cancer, according to results of a small trial reported here. Read... Read more »

Read More...

Heart drugs during breast cancer treatment can help women avoid cardiac issues

Admin • CCON • 11/11/2015

ORLANDO, Fla. — Many cancer treatments have a dark side — they can damage the heart. New research suggests this risk might be lowered in women with breast tumors if... Read more »

Read More...

Lee Memorial collaborative focuses on cancer, heart disease

Admin • CCON • 11/9/2015

Most of us know heart disease is the No. 1 killer of Americans, followed closely by cancer. It is a lesser known fact that cancer therapy can cause adverse effects on... Read more »

Read More...

Cardiotoxicity Low for Patients Receiving Paclitaxel, Trastuzumab for ERBB2+ Breast Cancer

Admin • CCON • 11/6/2015

Cardiac toxic effects from paclitaxel with trastuzumab, presenting as grade 3 or 4 left ventricular systolic dysfunction (LVSD) or asymptomatic left ventricular ejection fraction decline (LVEF), were low in patients... Read more »

Read More...